Bioprocessing has always been a bit late in adopting the latest engineering techniques, e.g. computational fluid dynamics to bioreactor design ...
Beam Therapeutics Inc. (NASDAQ:BEAM) on Saturday presented additional data from the Phase 1/2 clinical trial of BEAM-302 in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback